Charles River Laboratories International, Inc.

NYSE:CRL Rapporto sulle azioni

Cap. di mercato: US$9.6b

Charles River Laboratories International Gestione

Gestione criteri di controllo 4/4

Charles River Laboratories International Il CEO è Jim Foster, nominato in Jan1991, e ha un mandato di 33.83 anni. la retribuzione annua totale è $ 14.10M, composta da 10.4% di stipendio e 89.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.45% delle azioni della società, per un valore di $ 43.57M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5 anni e 7.3 anni.

Informazioni chiave

Jim Foster

Amministratore delegato

US$14.1m

Compenso totale

Percentuale dello stipendio del CEO10.4%
Mandato del CEO33.8yrs
Proprietà del CEO0.5%
Durata media del management5yrs
Durata media del Consiglio di amministrazione7.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Charles River Laboratories: Not The Right Time To Own At This Point In The Cycle

Nov 19

Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

Oct 26
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You

Oct 11
What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You

Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching

Sep 10
Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching

US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results

Aug 10
US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results

Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)

Aug 10

Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt

Jul 26
Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt

Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)

Jul 11
Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)

Charles River Laboratories: Fair Valuation Against Fundamentals

May 31

What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?

May 25
What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?

Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?

Apr 27
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?

Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings

Apr 11
Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings

Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Mar 27
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues

Feb 21
Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues

Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'

Feb 16

Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Jan 17
Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up

Jan 02
Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up

Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth

Dec 17
Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth

Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation

Nov 26

Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?

Nov 12
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?

Charles River: Q3 Points To Ongoing Deterioration

Nov 09

Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

Oct 27
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?

Oct 12
At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?

Charles River Laboratories: Diving Into The Lab (Rating Upgrade)

Oct 06

Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?

Aug 10
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?

Charles River Laboratories: Very Attractive After The Pullback

Jul 26

Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?

Jul 22
Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?

Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly

Jul 03
Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly

When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?

Jun 19
When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jim Foster rispetto agli utili di Charles River Laboratories International?
DataCompenso totaleStipendioGuadagni aziendali
Sep 28 2024n/an/a

US$413m

Jun 29 2024n/an/a

US$432m

Mar 30 2024n/an/a

US$439m

Dec 30 2023n/an/a

US$475m

Sep 30 2023n/an/a

US$475m

Jul 01 2023n/an/a

US$484m

Apr 01 2023n/an/a

US$496m

Dec 31 2022US$13mUS$1m

US$486m

Sep 24 2022n/an/a

US$436m

Jun 25 2022n/an/a

US$443m

Mar 26 2022n/an/a

US$422m

Dec 25 2021US$14mUS$1m

US$391m

Sep 25 2021n/an/a

US$397m

Jun 26 2021n/an/a

US$396m

Mar 27 2021n/an/a

US$375m

Dec 26 2020US$13mUS$1m

US$364m

Sep 26 2020n/an/a

US$301m

Jun 27 2020n/an/a

US$271m

Mar 28 2020n/an/a

US$248m

Dec 28 2019US$18mUS$1m

US$252m

Sep 28 2019n/an/a

US$231m

Jun 29 2019n/an/a

US$219m

Mar 30 2019n/an/a

US$227m

Dec 29 2018US$14mUS$1m

US$225m

Sep 29 2018n/an/a

US$135m

Jun 30 2018n/an/a

US$128m

Mar 31 2018n/an/a

US$129m

Dec 30 2017US$13mUS$1m

US$123m

Compensazione vs Mercato: La retribuzione totale di Jim ($USD 14.10M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 12.73M ).

Compensazione vs guadagni: La retribuzione di Jim è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Jim Foster (73 yo)

33.8yrs

Mandato

US$14,096,923

Compensazione

Mr. James C. Foster, J.D. has been the Chairman of the Board at Charles River Laboratories, Inc. (CRL) since 2000 and has been its Chief Executive Officer since 1992 and serves as its President since 1991....


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
James Foster
CEO, President & Chairman33.8yrsUS$14.10m0.45%
$ 43.6m
Flavia Pease
Corporate Executive VP & CFO2.5yrsUS$3.81m0.0049%
$ 474.7k
Birgit Girshick
Corporate Executive VP & COO3yrsUS$4.99m0.083%
$ 7.9m
Joseph LaPlume
Corporate Executive Vice President of Corporate Development & Strategy13.8yrsUS$3.06m0.021%
$ 2.0m
William Barbo
Corporate Executive Vice President of Community Relations8.1yrsUS$2.91m0.050%
$ 4.8m
Michael Knell
Corporate Senior VP & Chief Accounting Officer7.6yrsNessun dato0.010%
$ 999.3k
Julie Frearson
Corporate Senior VP & Chief Scientific Officer3yrsNessun datoNessun dato
Mark Mintz
Corporate Senior VP & Chief Information Officer3.4yrsNessun datoNessun dato
Todd Spencer
Corporate Vice President of Investor Relationsno dataNessun datoNessun dato
Matthew Daniel
Corporate Senior VP4.2yrsNessun datoNessun dato
Amy Cianciaruso
Corporate Vice President & Chief Communications Officerno dataNessun datoNessun dato
Victoria Creamer
Corporate Executive VP & Chief People Officer5.8yrsNessun dato0.020%
$ 1.9m

5.0yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di CRL è esperto e expertise (durata media dell'incarico 5 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
James Foster
CEO, President & Chairman35.8yrsUS$14.10m0.45%
$ 43.6m
Richard Wallman
Independent Director13.8yrsUS$339.77k0.022%
$ 2.1m
George Massaro
Lead Independent Director21.8yrsUS$371.02k0.010%
$ 995.4k
Virginia Wilson
Independent Director5.1yrsUS$346.02k0.0067%
$ 639.9k
Robert Bertolini
Independent Director13.8yrsUS$346.02k0.062%
$ 6.0m
Craig Thompson
Independent Director1.9yrsUS$437.78k0.0018%
$ 171.0k
Martin MacKay
Director7.3yrsUS$336.02k0.023%
$ 2.2m
Deborah Kochevar
Independent Director16.1yrsUS$339.77k0.014%
$ 1.4m
Nancy Andrews
Independent Director4.8yrsUS$339.77k0.0048%
$ 462.2k
George Llado
Independent Director4.1yrsUS$324.77k0.0049%
$ 467.0k
Reshema Kemps-Polanco
Independent Directorless than a yearNessun dato0.00033%
$ 31.7k

7.3yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CRL sono considerati esperti (durata media dell'incarico 7.3 anni).